A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors
NCT01358903
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
65
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
RO5429083
DRUG:
RO5429083
Sponsor
Hoffmann-La Roche